Acyl derivatives 5a-j and alkyl derivatives 7a'r of 4-dihydro-4-deoxy-4(R)-aminospectinomycin (1a) were prepared and tested for antibacterial activity. Only acyl compounds derived from long chain aliphatic acids or amino acids showed activity in vitro, but were inactive when tested in vivo. All alkyl derivatives were active in vitro. In vivo however only the short chain derivatives 7a-c were active. Compound 7h showed higher activity than spectinomycin.
In the preceding paper synthesis and biological properties of the epimeric 4-aminospectinomycins
(1) were described1).
Compound la possesses interesting antibiotic properties and is therefore a suitable starting material for further derivatives.
In this paper we describe preparation and biological properties of alkyl and acyl derivatives of la.
Synthesis
The derivatives were prepared according to Scheme 1.
Compound 3 was acylated with acid chlorides, mixed anhydrides with alkyl carbonates or Nhydroxysuccinimide esters to give 4a ti j (R1 see Table 1 ). In the cases of 4i and 4j, the corresponding N-Cbz amino acids were used.
Compounds 6a-r (R2 see Table 2 ) were synthesized from 2 by reductive amination (method 1), from 4 by reduction of the amide function (method 2) and from 3 by alkylation with alkyl halides (method 3) or activated olefins (method 4) or by reductive alkylation with carbonyl compounds (method 5). Compounds 6n and 6o were prepared by reduction of 6k and 6l. Removal of the carbobenzoxy groups by catalytic hydrogenation, in the cases of 4i and 4j by catalytic hydrogenation, followed by treatment with boron tristrifiuoroacetate gave 5a-j and 7a-r, as listed in Tables I and 2 . Synthesis of compounds 7 by methods 1 or 2 gave identical products, thus confirming the R-configuration of the compounds 7 obtained by method 1. The disubstituted derivatives 8a and 8b were prepared by reductive mcthylation of 6a and 6b, followed by removal of the carbobenzoxy groups.
Structure-Activity Relationships
The in vitro data of 5a-j and 7a-r are listed in Tables I and 2 . Simple acyl derivatives like 5a, g, h were inactive. Activity however could be obtained by increasing the chain length (5d, e, f) or introduction of an amino group (51, j). 5d, e, f showed remarkably good activity against E. coli and Pseudornonas.
Short alkyl chains led to compounds with antibacterial activity comparable to spectinomycin (7a, b, c). Increase in chain length led first to a decrease (7d, e) and then to an increase of activity, especially against Pseudomonas (7f, g).
Introduction of a carbonyl group into the alkyl chain led to enhanced activity (7k,1 compared with 7a) whereas other substituents like ethoxycarbonyl, hydroxy or anilinocarbonyl led to substances with weaker activity (7m, n, o, q, r) . Three benzyl derivatives were tested. Only 7j showed activity comparable to spectinomycin.
The dialkyl derivatives 8a and b, not shown in Tables I and 2 , are devoid of activity in vitro.
The in vitro activity was tested in mice infected with E. coli ATCC 11775. Most of the compounds were inactive at the highest subcutaneous dosage of 40 mg/kg. Only the short chain alkyl derivatives Capric acid (1.25 g, 7.3 mmole) and triethylamine (1.0 ml, 7.3 mmole) were dissolved in 20 ml of CH,Cl2i the mixture cooled to -10°C and isobutylchloroformate (0.69 ml, 7.3 mmole) added dropwise. After stirring for another 30 minutes at -10°C, 3 (4.0 g, 6.6 mmole) in 20 ml of CH2Cl2 was added. The mixture was stirred for one hour without external cooling, extracted with water (2 x 50 ml) and the organic layer dried (Na2SO,) and evaporated. Column chromatography (SiO2, CH2Cl2 -CH3OH, 18: 1) of the residue yielded 2.4 g (49 %) of 4c as a white powder: MS m/z 971 (M+ --3 TMSi).
The product was hydrogenated in 60 ml of 3 % HCl-EtOH with 1 g of 10 % Pd-C (room temperature, I atm., 2 hours). Removal of catalyst, concentration and trituration with ether afforded 1.65 g (93 %) of 5c as a white powder.
PMR (D2O, 80 MHz) 5 0.8 (t, broad, 3H, CH3), 1.25 (m, 14H, CH2, 3H, C-2 CH3), 1.5-1.8 (m, 2H, H-3), 2.3 (t, 2H, COCH2), 2.9 (s, broad, 6H, NCH3), 5.1 (s, 1H, H-10a); MS m/z 703, 775, 847, 919 (M+ +3 -6 TMSi).
4-Dihydro-4-deoxy-4(R)-benzoylaminospectinomycin Dihydrochloride (5g) To 3 (2.7 g, 4.5 mmole) in 40 ml of dioxane and 3 ml of water benzoylchloride (690 mg, 4.95 mmole) in 20 ml of dioxane was added dropwise (15 minutes, 10°C, pH 8 by addition of 2 N NaOH). After stirring for 30 minutes at 10°C the mixture was treated with 150 ml of a saturated NaCl solution, extracted with ethyl acetate and the organic layer dried (MgSO,) and evaporated. Trituration of the residue with 100 ml of ether gave 1.8 g (56.8 %) of 4g as a white powder: 1.7 g (2.4 mmole) of this product were hydrogenated with 1.5 g of 5 % Pd-C as described for 5c to give 1 g (85 %) of 5g as a white powder: PMR (CD3OD, 80 MHz) 6 1.28 (d, 3H, C-2 CH3), 1.90 (m, 2H, H-3), 2.9 (s broad, 6H, NCH3), 5.15 (s, IH, H-10a), 7.5-8 (m, 4H, aromatic); MS m/z 725, 797, 869 (M++4-6 TMSi).
4-Dihydro-4-deoxy-4(R)-(2-amino)-propionylaminospectinomycin
Trihydrochloride (5i) Dicyclohexylcarbodiimide (1.1 g, 5 mmole), dissolved in a small amount of THE was added to N-benzyloxycarbonyl-B-alanine (1.1 g, 5 mmole) and N-hydroxysuccinimide (0.6 g, 5 mmole) in THFdioxane. After stirring for 2 hours at 0°C and for 2 hours at room temperature, N,N'-dicyclohexylurea was filtered off. The filtrate was added to a solution of 3 (3.0 g, 5 mmole) in CH2Cl2 at 0°C, stirred for 5 hours at 0°C and for 10 hours at room temperature, evaporated and the residue purified by column chromatography (SiO2, CH2Cl2-CH3OH, 10: 1) to give 2.3 g (57%) of 4i: MS m/z 1022 (M++3 TMSi). Hydrogenation of 4i (0.8 g, 1 mmole) as described for 5c removed only the carbobenzoxy groups attached to the methylamino groups to give 0.5 g (92%) of a white powder: MS m/z 698 (M+ ,-5 TMSi). This THE JOURNAL OF ANTIBIOTIC 'S JAN. 1981 product (0.5 g, 0.9 mmole), dissolved in CF3COOH, was triturated with boron tristrifluoroacetate (3.5 g, 10 mmole) for 3 hours at 0°C, for 4 hours at room temperature and the solvent evaporated. The residue was dissolved repeatedly in CH3OH, the solvent evaporated, the residue dissolved in 3 % HClEtOH, again evaporated and the residue triturated with ether to give 0.3 g (80%) of 5i as a white powder: PMR (D20, 80 MHz) 5 1.3 (d, 3H, C-2 CH,), 1.9 (m, 2H, H-3), 2.9 (m, 6H, NCH3, 2H, COCH2); MS m/z 692, 764, 836, 908 (M++4'7 TMSi).
4-Dihydro-4-deoxy-4(R)-ethylaminospectinomycin Trihydrochloride (7b) (method 1)
Dry ethylamine (5.4 g, 120 mmole) in 60 ml of dry CH3OH was treated with 5 N HCl-CH3OH (20 ml, 100 mmole), followed by addition of 2 (12 g, 20 mmole) and, after cooling to 5°C, by addition of NaBH3CN (1.25 g, 20 mmole). The solution was stirred for 2 hours at 5°C, poured into 400 ml of 0.5 N HCl and extracted three times with 200 ml of ethyl acetate.
The organic extracts were washed with 3 portions of 300 ml of H2O and 10 ml of 2 N HCl.
The combined aqueous layers were brought to pH 8.5-9 by addition of 2 N NaOH and extracted two times with 300 ml of CH2Cl2. After drying (Na2SO,) and evaporating, column chromatography (Si02, CHCl3 -CH3OH, 5: 1) gave 5.9 g (47 %) of 6c as a white powder: MS m/z 845 (M++3 TMSi).
Hydrogenation of 1.9 g (3 mmole) of 6b as described for 5c afforded 1.2 g (85 %) of 7b as a white powder: PMR (CDC]3 -CD3OD, 80 MHz) 5 1.2-1.6 (m, 3H, CH2CH3, 3H, C-2 CH3), 1.9 (ni, 2H, H-3), 2.9 (s broad, 6H, NCH3), 5.1 (s, 1H, H-10a); MS m/z 577, 649, 721 (M+-;-3 -5 TMSi).
4-Dihydro-4-deoxy-4(R)-ethylaminospectinomycin
Trihydrochloride (7b) (method 2)
To a stirred suspension of NaBH, (1.13 g, 30 mmole) and 4a (1.93 g, 3 mmole) in dry dioxane (50m1) was added CF3000H (2.3 ml, 30 mmole) in 10 nil of dioxane (10 minutes, room temperature). After the evolution of gas had ceased, the mixture was heated to reflux for 2 hours, cooled, poured into 250 ml of H2O and extracted three times with 50 ml of CH2Cl2.
The combined extracts were washed with H2O, dried (Na2SO4) and evaporated to give, after column chromatography (SiO2, CHCl3 -CH3OH, 5: 1), 0.96 g (50%) of 6b as a colorless amorphous solid: MS m/z 845 (M++3 TMSi).
0.63 g (I mmole) of 6b were hydrogenated as described for 5c to give 0.35 g (74%) of 7b as a white powder. PMR, MS and TLC confirm identity with 7b prepared by method 1 : Rf 0.66 (SiO2, CHCl3 -CH3OH -aq.
conc. NH3, 1 : 1: 0.2).
4-Dihydro-4-deoxy-4(R)-p-methoxy-phenacylaminospectinomycin Trihydrochloride (7b) (method 3) 3 (3.6 g, 6 mmole), p-methoxyphenacylbromide (1.47 g, 6.3 mmole) and KZCO3 (840 mg, 6 mmole) were stirred in 21 ml of CH3CN (20 hours, room temperature).
The mixture was poured into 50 ml of water, extracted with ethyl acetate, the organic layer dried and evaporated. Column chromatography (SiO2, toluene -ethyl acetate, 4: 1) gave 1.4 g (30%) of 6p as a white powder. 700 mg (0.9 mmole) of this product in 300 ml of C2H5OH were hydrogenated with 700 mg of 5 % Pd-BaSO4 (7 hours, room temperature, 3 atm.). The solvent was evaporated (30°C), the residue dissolved in 30 nil of C2H5OH, treated with HCl-EtOH and then with ether to give 300 mg (57;x) of 7p: PMR (CDCl3 -CD3OD, 80 MHz) 6 1.3 (d, 3H, C-2 CH3), 2.1 (m, 2H, H-3), 2.9 (s, 6H, NCH3), 3.95 (s, 3H, OCH3), 5.25 (s, I H, H-10a), 7.0, 8.1 (q, 4H, aromatic); MS m/z 697, 769 (M++3 -4 TMSi).
4-Dihydro-4-deoxy-4(R)-(3-oxo)-butylaminospectinomycin
Trihydrochloride (7k) (method 4) Methyl vinyl ketone (0.78 ml, 9.5 mmole) in 10 nil of dry CH3OH was dropped into a stirred solution of 3 (5.7 g, 9.5 mmole) in dry CH3OH (40 ml, 40°C). The mixture was stirred for 1 hour at 40°C, evaporated, the residue dissolved in 0.1 N HCl (10 ml) and extracted three times with 30 ml of CHCl3. The combined extracts were dried and evaporated to a residue, purified by column chromatography (Si02, CHCl3 -CH3OH, 10:1) to give 6k (4.0 g, 62%) as an amorphous powder: MS m/z 887 (M++3 TMSi). 0.67 g (1 mmole) of 6k were hydrogenated as described for 5c to give 0.24 g (47%) of 7k as a white powder: PMR (CDCl3 -CD3OD, 80 MHz) 6 1.2 (d, 3H, C-2 CH3), 2.0 (m, 2H, H-3), 2.2 (s, 3H, COCH3), 2.5 (t, 2H, CH2CO), 2.9 (s broad, 6H, NCH3), 5.1 (s, 1H, H-10a); MS m/z 619, 691, 763 (M++3-5 TMSi).
4-Dihydro-4-deoxy-4(R)-(4-dimethylamino)-benzylaminospectinomycin
Trihydrochloride (7j) (method 5) 
